The first MEK inhibitor recommend by National Comprehensive Cancer Network (NCCN) for the treatment of NRASmut melanoma was the small‐molecule MEK1/2 inhibitor binimetinib (MEK162). This evidence concerns the gene MAP2K7 and melanoma.